Abstract
Background: Hyperthermia enhances the cytotoxicity of some chemotherapeutic agents. Both clinical and laboratory studies suggest melphalan may be an important drug when hyperthermia is added to chemotherapy treatments. Factors that may modify the thermal enhancement of melphalan were studied to optimize its clinical use with hyperthermia. Methods: The tumor studied was an early-generation isotransplant of a spontaneous C3Hf/Sed mouse fibrosarcoma, Fsa-II. All studies were performed under supervision of the Animal Care and Use Committee. Hyperthermia was administered by immersing the tumor-bearing foot into a constant temperature water bath. Four factors were studied: duration of hyperthermia, sequencing of hyperthermia and melphalan, intensity of hyperthermia, and tumor size. To study duration of hyperthermia tumors were treated at 41.5°C for 30 or 90 min immediately after intraperitoneal administration of melphalan. For sequencing of hyperthermia and melphalan, animals received hyperthermia treatment of tumors for 30 min at 41.5°C immediately after drug administration, both immediately and 3 h after administration of drug or only at 3 h after administration of drug. Intensity of hyperthermia was studied using heat treatment of tumors for 30 min at 41.5 or 43.5°C immediately following drug administration. Effect of tumor size was studied by delaying experiments until three times the tumor volume (113 mm3) was observed. Treatment of tumors was for 30 min at 41.5°C immediately following drug administration. Tumor response was studied by the mean tumor growth time. Results: Hyperthermia in the absence of melphalan had a small but significant effect on tumor growth time at 43.5°C but not at 41.5°C. Hyperthermia at 41.5°C immediately after melphalan administration doubled mean tumor growth time at 30 min and caused a threefold increase at 90 min (P=0.0002) when compared to tumors treated with melphalan alone at room temperature. Application of hyperthermia for one-half hour immediately following drug administration was the most effective in delaying tumor growth. No significant difference in mean tumor growth time was observed with an increase in temperature from 41.5 to 43.5°C. For large tumors heat alone and melphalan alone caused a moderate increase in tumor growth delay. These effects in large tumors were greatly increased by a combination of chemotherapy and hyperthermia. Conclusions: From our data it would appear that the administration of intraperitoneal melphalan immediately prior to 90 min of heat at 41.5°C may optimize anti-neoplastic activity. These data may be useful in formulating clinical protocols in which melphalan and heat are combined.
Similar content being viewed by others
References
Urano M, Kuroda M, Nishimura Y (1999) For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 15(2):79
Takemoto M, Kuroda M, Urano M, Nishimura Y, Kawasaki S, Kato H, Okumura Y, Akaki S, Kanazawa S, Asaumi J, Joja I, Hiraki (2003) The effect of various chemotherapeutic agents given with mild hyperthermia on different types of tumours. Int J Hyperthermia 19(2):193
Hahn GM (1979) Potential for therapy of drugs and hyperthermia. Cancer Res 39(6 Pt 2):2264
Engelhardt R (1987) Hyperthermia and drugs. Recent results. Cancer Res 104:136
Van Bree C, Beumer C, Rodermond HM, Haveman J, Bakker PJ (1999) Effectiveness of 2′,2′difluorodeoxycytidine (Gemcitabine) combined with hyperthermia in rat R-1 rhabdomyosarcoma in vitro and in vivo. Int J Hyperthermia 15(6):549
Urano M, Ling CC (2002) Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro. Int J Hyperthermia 18(4):307
Urano M, Gerweck LE, Epstein R, Cunningham M, Suit HD (1980) Response of a spontaneous murine tumor to hyperthermia: factors which modify the thermal response in vivo. Radiat Res 83(2):312
Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH (2003) Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 10(4):463
Sarosy G, Leyland-Jones B, Soochan P, Cheson BD (1988) The systemic administration of intravenous melphalan. J Clin Oncol 6(11):1768
Kuroda M, Urano M, Reynolds R (1997) Thermal enhancement of the effect of ifosfamide against a spontaneous murine fibrosarcoma, FSa-II. Int J Hyperthermia 13(1):125
Lienard D, Eggermont AM, Schraffordt Koops H, Kroon BB, Rosenkaimer F, Autier P, Lejeune FJ (1994) Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 4(Suppl 1):21
Olieman AF, van Ginkel RJ, Molenaar WM, Schraffordt Koops H, Hoekstra HJ (1998) Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile? Arch Orthop Trauma Surg 118(1–2):70
Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, Francois Y, Peyrat P, Panteix G, Vignal J, Gilly FN (2003) Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 21(5):799
Begg AC, Smith KA (1984) A bioassay for cyclophosphamide in blood, lung and tumour. Br J Cancer 49(1):49
Litterst CL, Schweitzer VG (1984) Increased tissue deposition and decreased excretion of platinum following administration of cisplatin to cisplatin-pretreated animals. Cancer Chemother Pharmacol 12(1):46
Song CW, Kang MS, Rhee JG, Levitt SH (1980) The effect of hyperthermia on vascular function, pH, and cell survival. Radiology 137(3):795
Haveman J, Rietbroek RC, Geerdink A, Van Rijn J, Bakker PJ (1995) Effect of hyperthermia on the cytotoxicity of 2′,2′-difluorodeoxycytidine (gemcitabine) in cultured SW1573 cells. Int J Cancer 62(5):62
Robins HI, d’Oleire F, Kutz M, Bird A, Schmitt-Tiggelaar CL, Cohen JD, Spriggs DR (1995) Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8 degrees C hyperthermia. Cancer Lett 89(1):55
Field SB, Law MP, Ahier RG, Morris CC (1982) Thermotolerance:recent studies of animal tissue of relevance to clinical practice. In: Kaarcher KH, Kogelnik HD, Reinartz G (eds) Progress in radiology-oncology. Raven Press, New York
Henle KJ, Dethlefsen LA (1978) Heat fractionation and thermotolerance: a review. Cancer Res 38(7):1843
Overgaard J, Nielsen OS (1983) The importance of thermotolerance for the clinical treatment with hyperthermia. Radiother Oncol 1(2):167
Xu M, Wright WD, Higashikubo R, Roti JR (1998) Intracellular distribution of hsp70 during long duration moderate hyperthermia. Int J Hyperthermia 14(2):211
Turman MA, Rosenfeld SL (1999) Heat shock protein 70 overexpression protects LLC-PK1 tubular cells from heat shock but not hypoxia. Kidney Int 55(1):189
Reeves OR (1972) Mechanisms of acquired resistance to acute heat shock in cultured mammalian cells. J Cell Physiol 79(2):157
Urano M, Kim MS (1983) Effect of hyperglycemia on thermochemotherapy of a spontaneous murine fibrosarcoma. Cancer Res 43(7):3041
Urano M, Kim MS, Kahn J, Kenton LA, Lim ML (1985) Effect of thermochemotherapy (combined cyclophosphamide and hyperthermia) given at various temperatures with or without glucose administration on a murine fibrosarcoma. Cancer Res 45(9):4162
Dudar TE, Jain RK (1984) Differential response of normal and tumor microcirculation to hyperthermia. Cancer Res 44(2):605
Thomlinson RH, Gray LH (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9:539
Overgaard J, Bichel P (1977) The influence of hypoxia and acidity on the hyperthermic response of malignant cells in vitro. Radiology 123(2):511
Gerweck LE, Kornblith PL, Burlett P, Wang J, Sweigert S (1977) Radiation sensitivity of cultured human glioblastoma cells. Radiology 125(1):231
Gerweck LE, Nygaard TG, Burlett M (1979) Response of cells to hyperthermia under acute and chronic hypoxic conditions. Cancer Res 39(3):966
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mohamed, F., Stuart, O.A., Glehen, O. et al. Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumor. Cancer Chemother Pharmacol 58, 719–724 (2006). https://doi.org/10.1007/s00280-006-0229-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-006-0229-2